![]() ![]() Maybe more important is "a wake-up call" from the study that mutating viruses can challenge vaccines. Especially in places where it's hard to get people to return for their second dose, the one-dose version could play a key role. infectious disease official, called that a messaging challenge - because the priority is to protect people from hospitalization and death, which J&J's vaccine appears to do. J&J's Mammen said direct comparisons are difficult because the Pfizer and Moderna vaccines weren't tested when the pandemic was so severe, with record levels of hospitalizations and deaths plus mutant versions of the virus sweeping some countries.ĭr. That makes for a dilemma: Wouldn't people given a choice want a vaccine found to offer much more protection? Early data is mixed on exactly how well all the different kinds work, but shots made by Pfizer and Moderna appear to be about 95% protective after the second dose. When the vaccinated did become infected, they had a milder illness.ĭefeating the scourge that has killed more than 2 million people worldwide will require vaccinating billions, and the shots being rolled out in different countries so far all require two doses a few weeks apart for full protection. Researchers tracked illnesses starting 28 days after vaccination - about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.Īfter day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to "regular COVID or these particularly nasty variants," Mammen said. These are preliminary findings from a study of 44,000 volunteers that isn't completed yet. J&J wouldn't say exactly how much could be ready to ship as soon as U.S. by June - and a billion doses globally by the end of the year. It expects to supply 100 million doses to the U.S. The company said within a week, it will file an application for emergency use in the U.S., and then abroad. Matt Hepburn of Operation Warp Speed, the U.S. ![]() With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.īut with some other competing vaccines shown to be 95% effective after two doses, at question is whether somewhat less protection is an acceptable tradeoff to get more shots in arms quickly. Mathai Mammen, global research chief for J&J's Janssen Pharmaceutical unit, told The Associated Press. "Gambling on one dose was certainly worthwhile," Dr. Newsletter sign-up: Get The COVID-19 Brief sent to your inbox.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |